WHAT THE HUMAN DATA SAY
Evidence before enthusiasm.
Small trials in older or healthy adults suggest that selected low-dose or intermittent regimens can be feasible, but benefits across function, disease prevention and lifespan remain uncertain. Sirolimus is FDA-approved for other indications—not aging.
This grade reflects clinically meaningful human evidence for the use described here. It is not a score for popularity, mechanism, animal lifespan results or the number of products already being sold.
HOW IT FITS
A practical role—without pretending it is universal.
This belongs in a licensed clinician relationship with informed consent, baseline evaluation, medication review and an explicit monitoring and stop plan. The Modern Bio does not provide a self-dosing protocol.
TRACK WHAT MATTERS
Know whether it is creating value.
CBC, lipids, glucose and organ function as directed
Oral ulcers, infection, wound healing and edema
The exact goal and whether benefit is objectively present
SAFETY & BOUNDARIES
What should make you pause.
- Immunosuppression, infection, mouth ulcers, lipid and glucose changes, edema, blood-count changes, drug interactions and impaired wound healing are material risks.
- Pregnancy, active infection, vaccination timing, surgery and cancer history require careful medical review.
- Never purchase or dose it from an unverified source.
BOOK CONNECTIONS
Where this idea enters the longevity conversation.
Book inclusion explains why the idea is culturally important; the evidence grade above determines how strongly The Modern Bio treats the claim.